Annals of internal medicine Journal Impact Factor & Information

Publisher: American College of Physicians, American College of Physicians

Journal description

Established in 1927 by the American College of Physicians (ACP), the Annals of Internal Medicine is the leading journal for studies in internal medicine. The purpose of the journalñto promote excellence in the clinical practice of internal medicineñis supported by presentation of a wide variety of experimental and clinical subject matter in the Article, Brief Communication, Update, and Review formats. And to support the belief that physicians should also be well-informed citizens of both the medical community and society at large, Annals offers background and discussion of issues that influence both physicians and patients. This information is primarily carried in the Perspective, In the Balance, and Editorial formats. In addition, the journal presents personal narratives in the On Being a Doctor and the On Being a Patient formats that convey the feeling and the art of medicine.

Current impact factor: 17.81

Impact Factor Rankings

2015 Impact Factor Available summer 2016
2014 Impact Factor 17.81
2013 Impact Factor 16.104
2012 Impact Factor 13.976
2011 Impact Factor 16.733
2010 Impact Factor 16.729
2009 Impact Factor 16.225
2008 Impact Factor 17.457
2007 Impact Factor 15.516
2006 Impact Factor 14.78
2005 Impact Factor 13.254
2004 Impact Factor 13.114
2003 Impact Factor 12.427
2002 Impact Factor 11.414
2001 Impact Factor 11.13
2000 Impact Factor 9.833
1999 Impact Factor 10.097
1998 Impact Factor 10.9
1997 Impact Factor 12.047
1996 Impact Factor 11.21
1995 Impact Factor 9.92
1994 Impact Factor 9.887
1993 Impact Factor 9.297
1992 Impact Factor 10.217

Impact factor over time

Impact factor

Additional details

5-year impact 17.47
Cited half-life >10.0
Immediacy index 5.13
Eigenfactor 0.11
Article influence 8.11
Website Annals of Internal Medicine website
Other titles Annals of internal medicine (Online), Annals of internal medicine,
ISSN 1539-3704
OCLC 37354934
Material type Online system or service, Periodical, Internet resource
Document type Internet Resource, Computer File, Journal / Magazine / Newspaper

Publisher details

American College of Physicians

  • Pre-print
    • Archiving status unclear
  • Post-print
    • Author cannot archive a post-print version
  • Restrictions
    • 6 months embargo
  • Conditions
    • Authors may deposit in PubMed Central only
    • Publisher's version/PDF cannot be used
    • Set statement to accompany deposit (see policy)
    • Publisher last reviewed on 04/11/2014
  • Classification
    ​ white

Publications in this journal

  • Oluwaseun Falade-Nwulia · Eric C Seaberg · Anna E Snider · Charles R Rinaldo · John Phair · Mallory D Witt · Chloe L Thio
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: Men who have sex with men (MSM) are at high risk for hepatitis B virus (HBV) infection. Data on the effect of highly active antiretroviral therapy (HAART) on incident HBV infection in HIV-infected and HIV-uninfected MSM are limited. Objective: To determine predictors of incident HBV infection in MSM during pre-HAART and HAART periods. Design: Observational cohort study. Setting: Cohort of MSM who have, or are at risk for, HIV infection. Patients: 2375 HBV-uninfected MSM in the Multicenter AIDS Cohort Study. Measurements: Poisson regression was used to compare incidence rates of HBV infection in the pre-HAART and HAART eras and to identify factors associated with incidence of HBV infection. Results: In 25 322 person-years of follow-up, 244 incident HBV infections occurred. The unadjusted incidence rate was higher in HIV-infected MSM than in HIV-uninfected MSM (incidence rate ratio [IRR], 1.9 [95% CI, 1.5 to 2.4]) and was significantly lower in the HAART era than in the pre-HAART era among HIV-infected (IRR, 0.2 [CI, 0.1 to 0.4]) and HIV-uninfected (IRR, 0.3 [CI, 0.2 to 0.4]) MSM. Age younger than 40 years (IRR, 2.3 [CI, 1.7 to 3.0]), more than 1 recent sexual partner (IRR, 3.1 [CI, 2.3 to 4.2]), and HIV infection (IRR, 2.4 [CI, 1.8 to 3.1]) were independently associated with higher incidence of HBV infection, whereas HBV vaccination was protective (IRR, 0.3 [CI, 0.2 to 0.4]). Highly active antiretroviral therapy with HIV RNA levels less than 400 copies/mL was associated with protection (IRR, 0.2 [CI, 0.1 to 0.5]), but HAART in those with HIV RNA levels of 400 copies/mL or greater was not. Limitation: The observational nature limits inferences about causality. Conclusion: Effective HAART is associated with lower incidence of HBV infection; however, even in the HAART era, incidence of HBV infection remains high among MSM. Primary funding source: National Institute of Allergy and Infectious Diseases.
    Annals of internal medicine 10/2015; DOI:10.7326/M15-0547
  • Shuo-Ming Ou · Chia-Jen Shih · Pei-Wen Chao · Hsi Chu · Shu-Chen Kuo · Yi-Jung Lee · Shuu-Jiun Wang · Chih-Yu Yang · Chih-Ching Lin · Tzeng-Ji Chen · Der-Cherng Tarng · Szu-Yuan Li · Yung-Tai Chen
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: Recent studies concluded that dipeptidyl peptidase-4 (DPP-4) inhibitors provide glycemic control but also raised concerns about the risk for heart failure in patients with type 2 diabetes mellitus (T2DM). However, large-scale studies of the effects on cardiovascular outcomes of adding DPP-4 inhibitors versus sulfonylureas to metformin therapy remain scarce. Objective: To compare clinical outcomes of adding DPP-4 inhibitors versus sulfonylureas to metformin therapy in patients with T2DM. Design: Nationwide study using Taiwan's National Health Insurance Research Database. Setting: Taiwan. Patients: All patients with T2DM aged 20 years or older between 2009 and 2012. A total of 10 089 propensity score-matched pairs of DPP-4 inhibitor users and sulfonylurea users were examined. Measurements: Cox models with exposure to sulfonylureas and DPP-4 inhibitors included as time-varying covariates were used to compare outcomes. The following outcomes were considered: all-cause mortality, major adverse cardiovascular events (MACEs) (including ischemic stroke and myocardial infarction), hospitalization for heart failure, and hypoglycemia. Patients were followed until death or 31 December 2013. Results: DPP-4 inhibitors were associated with lower risks for all-cause death (hazard ratio [HR], 0.63 [95% CI, 0.55 to 0.72]), MACEs (HR, 0.68 [CI, 0.55 to 0.83]), ischemic stroke (HR, 0.64 [CI, 0.51 to 0.81]), and hypoglycemia (HR, 0.43 [CI, 0.33 to 0.56]) compared with sulfonylureas as add-on therapy to metformin but had no effect on risks for myocardial infarction and hospitalization for heart failure. Limitation: Observational study design. Conclusion: Compared with sulfonylureas, DPP-4 inhibitors were associated with lower risks for all-cause death, MACEs, ischemic stroke, and hypoglycemia when used as add-ons to metformin therapy. Primary funding source: None.
    Annals of internal medicine 10/2015; DOI:10.7326/M15-0308
  • Daichi Shimbo · Marwah Abdalla · Louise Falzon · Raymond R Townsend · Paul Muntner
    [Show abstract] [Hide abstract]
    ABSTRACT: Hypertension, a common risk factor for cardiovascular disease, is usually diagnosed and treated based on blood pressure readings obtained in the clinic setting. Blood pressure may differ considerably when measured inside versus outside of the clinic setting. Over the past several decades, evidence has accumulated on the following 2 approaches for measuring blood pressure outside of the clinic: ambulatory blood pressure monitoring (ABPM) and home blood pressure monitoring (HBPM). Both of these methods have a stronger association with cardiovascular disease outcomes than clinic blood pressure measurement. Controversy exists about whether ABPM or HBPM is superior for estimating risk for cardiovascular disease and under what circumstances these methods should be used in clinical practice for assessing blood pressure outside of the clinic. This review describes ABPM and HBPM procedures, the blood pressure phenotypic measurements that can be ascertained, and the evidence that supports the use of each approach to measuring blood pressure outside of the clinic. It also describes barriers to the successful implementation of ABPM and HBPM in clinical practice, proposes core competencies for the conduct of these procedures, and highlights important areas for future research.
    Annals of internal medicine 10/2015; DOI:10.7326/M15-1270
  • Richard J Comi
    Annals of internal medicine 10/2015; DOI:10.7326/M15-2179
  • Yftach Gepner · Rachel Golan · Ilana Harman-Boehm · Yaakov Henkin · Dan Schwarzfuchs · Ilan Shelef · Ronen Durst · Julia Kovsan · Arkady Bolotin · Eran Leitersdorf · [...] · Benjamin Sarusi · Sivan Ben-Avraham · Anders Helander · Uta Ceglarek · Michael Stumvoll · Matthias Blüher · Joachim Thiery · Assaf Rudich · Meir J Stampfer · Iris Shai
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: Recommendations for moderate alcohol consumption remain controversial, particularly in type 2 diabetes mellitus (T2DM). Long-term randomized, controlled trials (RCTs) are lacking. Objective: To assess cardiometabolic effects of initiating moderate alcohol intake in persons with T2DM and whether the type of wine matters. Design: 2-year RCT (CASCADE [CArdiovaSCulAr Diabetes & Ethanol] trial). ( NCT00784433). Setting: Ben-Gurion University of the Negev-Soroka Medical Center and Nuclear Research Center Negev, Israel. Patients: Alcohol-abstaining adults with well-controlled T2DM. Intervention: Patients were randomly assigned to 150 mL of mineral water, white wine, or red wine with dinner for 2 years. Wines and mineral water were provided. All groups followed a Mediterranean diet without caloric restriction. Measurements: Primary outcomes were lipid and glycemic control profiles. Genetic measurements were done, and patients were followed for blood pressure, liver biomarkers, medication use, symptoms, and quality of life. Results: Of the 224 patients who were randomly assigned, 94% had follow-up data at 1 year and 87% at 2 years. In addition to the changes in the water group (Mediterranean diet only), red wine significantly increased high-density lipoprotein cholesterol (HDL-C) level by 0.05 mmol/L (2.0 mg/dL) (95% CI, 0.04 to 0.06 mmol/L [1.6 to 2.2 mg/dL]; P < 0.001) and apolipoprotein(a)1 level by 0.03 g/L (CI, 0.01 to 0.06 g/L; P = 0.05) and decreased the total cholesterol-HDL-C ratio by 0.27 (CI, -0.52 to -0.01; P = 0.039). Only slow ethanol metabolizers (alcohol dehydrogenase alleles [ADH1B*1] carriers) significantly benefited from the effect of both wines on glycemic control (fasting plasma glucose, homeostatic model assessment of insulin resistance, and hemoglobin A1c) compared with fast ethanol metabolizers (persons homozygous for ADH1B*2). Across the 3 groups, no material differences were identified in blood pressure, adiposity, liver function, drug therapy, symptoms, or quality of life, except that sleep quality improved in both wine groups compared with the water group (P = 0.040). Overall, compared with the changes in the water group, red wine further reduced the number of components of the metabolic syndrome by 0.34 (CI, -0.68 to -0.001; P = 0.049). Limitation: Participants were not blinded to treatment allocation. Conclusion: This long-term RCT suggests that initiating moderate wine intake, especially red wine, among well-controlled diabetics as part of a healthy diet is apparently safe and modestly decreases cardiometabolic risk. The genetic interactions suggest that ethanol plays an important role in glucose metabolism, and red wine's effects also involve nonalcoholic constituents. Primary funding source: European Foundation for the Study of Diabetes.
    Annals of internal medicine 10/2015; DOI:10.7326/M14-1650
  • Hilary Daniel · Shari Erickson
    [Show abstract] [Hide abstract]
    ABSTRACT: Retail health clinics are walk-in clinics located in retail stores or pharmacies that are typically staffed by nurse practitioners or physician assistants. When they entered the marketplace in the early 2000s, retail clinics offered a limited number of services for low-acuity conditions that were paid for out of pocket by the consumer. Over the past decade, business models for these clinics have evolved to accept public and private health insurance, and some are expanding their services to include diagnosis, treatment, and management of chronic conditions. Retail health clinics are one of several methods of health care delivery that challenge the traditional primary care delivery model. The positions and recommendations offered by the American College of Physicians in this paper are intended to establish a framework that underscores patient safety, communication, and collaboration among retail health clinics, physicians, and patients.
    Annals of internal medicine 10/2015; DOI:10.7326/M15-0571
  • Comilla Sasson · Jason S Haukoos
    Annals of internal medicine 10/2015; DOI:10.7326/M15-2192
  • Prachi Sanghavi · Anupam B Jena · Joseph P Newhouse · Alan M Zaslavsky
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: Most Medicare patients seeking emergency medical transport are treated by ambulance providers trained in advanced life support (ALS). Evidence supporting the superiority of ALS over basic life support (BLS) is limited, but some studies suggest ALS may harm patients. Objective: To compare outcomes after ALS and BLS in out-of-hospital medical emergencies. Design: Observational study with adjustment for propensity score weights and instrumental variable analyses based on county-level variations in ALS use. Setting: Traditional Medicare. Patients: 20% random sample of Medicare beneficiaries from nonrural counties between 2006 and 2011 with major trauma, stroke, acute myocardial infarction (AMI), or respiratory failure. Measurements: Neurologic functioning and survival to 30 days, 90 days, 1 year, and 2 years. Results: Except in cases of AMI, patients showed superior unadjusted outcomes with BLS despite being older and having more comorbidities. In propensity score analyses, survival to 90 days among patients with trauma, stroke, and respiratory failure was higher with BLS than ALS (6.1 percentage points [95% CI, 5.4 to 6.8 percentage points] for trauma; 7.0 percentage points [CI, 6.2 to 7.7 percentage points] for stroke; and 3.7 percentage points [CI, 2.5 to 4.8 percentage points] for respiratory failure). Patients with AMI did not exhibit differences in survival at 30 days but had better survival at 90 days with ALS (1.0 percentage point [CI, 0.1 to 1.9 percentage points]). Neurologic functioning favored BLS for all diagnoses. Results from instrumental variable analyses were broadly consistent with propensity score analyses for trauma and stroke, showed no survival differences between BLS and ALS for respiratory failure, and showed better survival at all time points with BLS than ALS for patients with AMI. Limitation: Only Medicare beneficiaries from nonrural counties were studied. Conclusion: Advanced life support is associated with substantially higher mortality for several acute medical emergencies than BLS. Primary funding source: National Science Foundation, Agency for Healthcare Research and Quality, and National Institutes of Health.
    Annals of internal medicine 10/2015; DOI:10.7326/M15-0557
  • Mark S Lachs · S Duke Han
    Annals of internal medicine 10/2015; DOI:10.7326/M15-0882
  • Albert L Siu
    [Show abstract] [Hide abstract]
    ABSTRACT: Description: Update of the 2007 U.S. Preventive Services Task Force (USPSTF) reaffirmation recommendation statement on screening for high blood pressure in adults. Methods: The USPSTF reviewed the evidence on the diagnostic accuracy of different methods for confirming a diagnosis of hypertension after initial screening and the optimal rescreening interval for diagnosing hypertension. Population: This recommendation applies to adults aged 18 years or older without known hypertension. Recommendation: The USPSTF recommends screening for high blood pressure in adults aged 18 years or older. (A recommendation).
    Annals of internal medicine 10/2015; DOI:10.7326/M15-2223
  • Annals of internal medicine 10/2015; 163(7):564-565. DOI:10.7326/L15-5141-2
  • Annals of internal medicine 10/2015; 163(7):565-566. DOI:10.7326/L15-5142-2
  • Annals of internal medicine 10/2015; 163(7):566-567. DOI:10.7326/L15-5144-2
  • Annals of internal medicine 10/2015; 163(7):553. DOI:10.7326/M15-0226
  • [Show abstract] [Hide abstract]
    ABSTRACT: Pelvic examinations have historically been a part of regular preventive care. However, because women can now be screened for cervical cancer at intervals up to every 5 years, the question of whether women need to be seen annually for routine pelvic examinations has arisen. In July 2014, the American College of Physicians (ACP) issued a guideline presenting the available evidence on screening for pathologic conditions using pelvic examination in adult, asymptomatic women at average risk. The American College of Obstetricians and Gynecologists (ACOG) Committee on Gynecologic Practice had previously issued a committee opinion in August 2012 on the need for annual examinations and provided guidelines on important elements of this procedure, including when to examine asymptomatic women. ACOG reaffirmed its initial position after publication of the ACP guideline. The guidelines differ-the ACP guideline recommends against and the ACOG committee opinion recommends in favor of routine annual pelvic examination. This paper summarizes a discussion between an internist and a gynecologist on how they would balance these recommendations in general and what they would suggest for an individual patient.
    Annals of internal medicine 10/2015; 163(7):537-547. DOI:10.7326/M15-1220
  • Annals of internal medicine 10/2015; 163(7):566. DOI:10.7326/L15-5144
  • Annals of internal medicine 10/2015; 163(7):565. DOI:10.7326/L15-5142
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: Cancer is increasingly common among persons with HIV. Objective: To examine calendar trends in cumulative cancer incidence and hazard rate by HIV status. Design: Cohort study. Setting: North American AIDS Cohort Collaboration on Research and Design during 1996 to 2009. Participants: 86 620 persons with HIV and 196 987 uninfected adults. Measurements: Cancer type-specific cumulative incidence by age 75 years and calendar trends in cumulative incidence and hazard rates, each by HIV status. Results: Cumulative incidences of cancer by age 75 years for persons with and without HIV, respectively, were as follows: Kaposi sarcoma, 4.4% and 0.01%; non-Hodgkin lymphoma, 4.5% and 0.7%; lung cancer, 3.4% and 2.8%; anal cancer, 1.5% and 0.05%; colorectal cancer, 1.0% and 1.5%; liver cancer, 1.1% and 0.4%; Hodgkin lymphoma, 0.9% and 0.09%; melanoma, 0.5% and 0.6%; and oral cavity/pharyngeal cancer, 0.8% and 0.8%. Among persons with HIV, calendar trends in cumulative incidence and hazard rate decreased for Kaposi sarcoma and non-Hodgkin lymphoma. For anal, colorectal, and liver cancer, increasing cumulative incidence, but not hazard rate trends, were due to the decreasing mortality rate trend (-9% per year), allowing greater opportunity to be diagnosed. Despite decreasing hazard rate trends for lung cancer, Hodgkin lymphoma, and melanoma, cumulative incidence trends were not seen because of the compensating effect of the declining mortality rate. Limitation: Secular trends in screening, smoking, and viral co-infections were not evaluated. Conclusion: Cumulative cancer incidence by age 75 years, approximating lifetime risk in persons with HIV, may have clinical utility in this population. The high cumulative incidences by age 75 years for Kaposi sarcoma, non-Hodgkin lymphoma, and lung cancer support early and sustained antiretroviral therapy and smoking cessation. Primary funding source: National Institutes of Health.
    Annals of internal medicine 10/2015; 163(7):507-518. DOI:10.7326/M14-2768
  • Annals of internal medicine 10/2015; 163(7):562-563. DOI:10.7326/M15-1202